HIGHLY ATTENUATED SIV VIF DNA VACCINES

高度减毒 SIV VIF DNA 疫苗

• 批准号: 7562168
• 负责人: Ellen Elizabeth Sparger
• 金额: $ 18.16万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562168
• 关键词: Attenuated; Cells; Computer Retrieval of Information on Scientific Projects Database; Cytidine Deaminase; Funding; Grant; Institution; Proteins; Research; Research Personnel; Resources; Source; Subfamily lentivirinae; Tissues; United States National Institutes of Health; Vaccines; Viral; Virion; Virus; cellular targeting; vif Genes

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: The accessory gene vif of lentiviruses is required for efficient viral replication. Vif inhibits virion incorporation of a cellular cytidine deaminase, APOBEC3G, by targeting this cellular protein for proteosomal degradation. A vif-deleted virus may be persistent in the host, although at extremely low levels and restricted to specific tissues or cell subsets with reduced expression of APOBEC3 proteins.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 目的：有效的病毒复制需要慢病毒的辅助基因VIF。 VIF通过将这种细胞蛋白靶向蛋白质体降解，抑制细胞胞苷脱氨酶Apobec3g的病毒体掺入。宿主可能会持续存在VIF缺乏的病毒，尽管水平极低，并且仅限于特定的组织或细胞亚群，并降低了APOBEC3蛋白的表达。